Ethical challenges in neonatal research: Summary report of the ethics group of the newborn drug development initiative

Clinical Therapeutics

Volumn 28, Issue 9, 2006, Pages 1399-1407

  Baer, Gerri R ^a   Nelson, Robert M ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

ethics; fetal research; human experimentation, infant; neonatal pharmacology; newborn

Indexed keywords

ANTICONVULSIVE AGENT; METHYLXANTHINE; PLACEBO;

APNEA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; EPILEPSY; HUMAN; INFORMED CONSENT; MEDICAL SOCIETY; METHODOLOGY; NEWBORN; NEWBORN CARE; PATIENT PARTICIPATION; RANDOMIZED CONTROLLED TRIAL; RESEARCH ETHICS; RISK BENEFIT ANALYSIS;

BIOMEDICAL RESEARCH; DRUG EVALUATION; ETHICS, MEDICAL; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; PHARMACOLOGY, CLINICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33750085880     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.09.008     Document Type: Article

References (46)

1. Barr J., Brenner-Zada G., Heiman E., et al. Unlicensed and off-label medication use in a neonatal intensive care unit: A prospective study. Am J Perinatol 19 (2002) 67-72
2. Conroy S. Unlicensed and off label drug use for paediatric patients. Optimal dosing schedules with gentamicin are needed for premature neonates. BMJ 317 (1998) 204-205
3. Conroy S., and McIntyre J. The use of unlicensed and off-label medicines in the neonate. Semin Fetal Neonatal Med. 10 (2005) 115-122
4. Conroy S., McIntyre J., and Choonara I. Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed. 80 (1999) F142-F145
5. Roberts R., Rodriguez W., Murphy D., and Crescenzi T. Pediatric drug labeling: Improving the safety and efficacy of pediatric therapies. JAMA 290 (2003) 905-911
6. Chalumeau M., Tonnelier S., D'Athis P., et al., Pediatric Fluoroquinolone Safety Study Investigators. Fluoroquinolone safety in pediatric patients: A prospective, multicenter, comparative cohort study in France. Pediatrics 111 (2003) e714-e719
7. Choonara I. Unlicensed and off-label drug use in children: Implications for safety. ExpertOpin Drug Saf 3 (2004) 81-83
8. Choonara I., and Conroy S. Unlicensed and off-label drug use in children: Implications for safety. Drug Saf. 25 (2002) 1-5
9. Horen B., Montastruc J.L., and Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol. 54 (2002) 665-670
10. Neubert A., Dormann H., Weiss J., et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf 27 (2004) 1059-1067
11. Turner S., Nunn A.J., Fielding K., and Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: A prospective study. Acta Peddaatr 88 (1999) 965-968
12. Ufer M., Kimland E., and Bergman U. Adverse drug reactions and off-label prescribing for paediatric outpatients: A one-year survey of spontaneous reports in Sweden. Pharmacoepidemiol Drug Saf 13 (2004) 147-152
13. Nelson R.M., and Ross L.F. In defense of a single standard of research risk for all children. J Pediatr. 147 (2005) 565-566
14. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Offcial Journal of the European Communities L121 (2001) 34-44
15. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Research Involving Children: Report and Recommendations (1977), US Government Printing Office, Washington, DC
16. Available at:. World Medical Association. Declaration of Helsinki. Accessed August 22, 2006 (2004), World Medical Association, Tokyo, Japan. http://www.wma.net/e/policy/b3htm
17. Section 4.8.14. Food and Drug Administration. ICH; Good Clinical Practice: Consolidated Guideline. Federal Register. 62 (1997) 25692-25709
18. Food and Drug Administration. ICH; E11: Clinical Investigation of Medicinal Products in the Pediatric Population. Federal Register 65 (April 12, 2000) 19777-19781
19. Pediatric Research Equity Act of 2003. 117 Stat. 108th Congress ed. (2003) 1936-1943
20. March. National Institutes of Health. Questions and Answers about the NIH Policy on the Inclusion of Children as Participants in Research Involving Human Subjects. Accessed August 22, 2006 (1999). http://grants.nih.gov/grants/funding/children/pol_children_ga.htm#g18name Accessed August 22, 2006
21. Coffey M.J., Wilford B., and Ross L.F. Ethical assessment of clinical asthma trials including children subjects. Pediatrics 113 (2004) 87-94
22. Walsh M.C., Szefler S., Davis J., et al. Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics 117 (2006) S52-S56
23. Short B.L., Van Meurs K., Evans J.R., and Cardiology Group. Summary proceedings from the cardiology group on cardiovascular instability in preterm infants. Pediatrics 117 (2006) 534-539
24. Roth S.J., Adatia I., Pearson G.D., and Members of the Cardiology Group. Summary proceedings from the cardiology group on postoperative cardiac dysfunction. Pediatrics 117 (2006) S40-S46
25. Perlman J.M. Summary proceedings from the neurology group on hypoxic-ischemic encephalopathy. Pediatrics 117 (2006) S28-S33
26. Finer N.N., Higgins R., Kattwinkel J., and Martin R.J. Summary proceedings from the apnea-of-prematurity group. Pediatrics 117 (2006) S47-S51
27. Clancy R.R. Summary proceedings from the neurology group on neonatal seizures. Pediatrics 117 (2006) S23-S27
28. Anand K.J., Aranda J.V., Berde C.B., et al. Summary proceedings from the neonatal pain-control group. Pediatrics 117 (2006) 59-522
29. Committee on Clinical Research Involving Children. Board on Health Sciences Policy, Institute of Medicine. In: Field M.J., and Bergman R.E. (Eds). Ethical Conduct of Clinical Research Involving Children (2004), The National Academies Press, Washington, DC 138
30. Ethical and policy issues in research involving human participants. Report and Recommendations of the National Bioethics Advisory Commission Vol I (2001), National Bioethics Advisory Commission, Bethesda, Md
31. Weijer C. The ethical analysis of risk. J Law Med Ethics 28 (2000) 344-361
32. Food and Drug Administration. International Conference on Harmonisation; Choice of Control Group in Clinical Trials. Federal Register 64 (September 24, 1999) 51767
33. August. Tri-Council Policy Statement: Ethical conduct for research involving humans. Accessed August 22, 2006 (1998), Medical Research Council of Canada. Accessed August 22, 2006 cnerh.org/english/code_2/ Accessed August 22, 2006
34. Giacoia G.P., Birenbaum D.L., Sachs H.C., and Mattison D.R. The newborn drug development initiative. Pediatrics 117 (2006) S1-S8
35. Anand K.J., Aranda J.V., Berde C.B., et al. Analgesia and anesthesia for neonates: Study design and ethical issues. Clin Ther. 27 (2005) 814-843
36. Anand K.J., Johnston C.C., Oberlander T.F., et al. Analgesia and local anesthesia during invasive procedures in the neonate. Clin Ther. 27 (2005) 844-876
37. Mann H. Controversial choice of a control intervention in a trial of ventilator therapy in ARDS: Standard of care arguments in a randomised controlled trial. J Med Ethics. 31 (2005) 548-553
38. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 342 (2000) 1301-1308
39. Phibbs R.H., Ballard R.A., Clements J.A., et al. Initial clinical trial of EXOSURF, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease. Pediatrics 88 (1991) 1-9
40. Shankaran S., Laptook A.R., Ehrenkranz R.A., et al., National Institute of Child Health and Human Development Neonatal Research Network. Whole-body hy pothermia for neonates with hypoxicischemic encephalopathy. N Engl J Med. 353 (2005) 1574-1584
41. Gluckman P.D., Wyatt J.S., Azzopardi D., et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: Multicentre randomised trial. Lancet 365 (2005) 663-670
42. Morris M.C., Nadkarni V.M., Ward F.R., and Nelson R.M. Exception from informed consent for pediatric resus citation research: Community consultation for a trial of brain cooling after in-hospital cardiac arrest. Pediatrics 114 (2004) 776-781
43. Department of Health and Human Services. Subpart B-additional protections for pregnant women, human fetuses and neonates involved in research. Federal Register 66 (November 13, 2001) 56778-56780
44. dated. Letter addressed to Irene StithColeman, PhD. Accessed April 12, 2006 (September 4, 2001). http://www.hhs.gov/ohrp/nhrpac/documents/oct01c.pdf Accessed April 12, 2006
45. Rogers C.G., Tyson J.E., Kennedy K.A., et al. Conventional consent with opting in versus simplified consent with opting out: An exploratory trial for studies that do not increase patient risk. J Pediatr 132 (1998) 606-611
46. Department of Health and Human Services. 45 CFR Part 46: Waiver of informed consent requirements in certain emergency research. Federal Register 61 (October 2, 1996) 51531